Diagnostic and prognostic methods for estrogen-induced cancers
AssigneeThe University of Newcastle
InventorPradeep S. Tanwar
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for detecting an estrogen-induced cancer in a subject, for identifying a subject at risk of developing an estrogen-induced cancer and for determining or predicting prognosis for a subject with an estrogen-induced cancer. The methods of the disclosure comprise determining the level of expression of ALPPL2 in a biological sample, typically a blood sample, obtained from a subject.
Claims12
A method for treating a subject determined to have an estrogen-induced cancer, the method comprising:
- (a) obtaining or having obtained a biological sample from the subject;
- (b) performing or having performed a biochemical assay on the biological sample to identify the subject as having a level of expression of placental-like alkaline phosphatase 2 (ALPPL2) in the biological sample that is greater than a threshold level from one or more reference samples and is indicative of a presence of the estrogen-induced cancer in the subject;
- and
- (c) administering a therapy to the subject identified in (b) that is capable of treating the estrogen-induced cancer, wherein the therapy comprises chemotherapy, surgery, or radiotherapy,
- wherein the estrogen-induced cancer is early-stage ovarian cancer or early-stage endometrial cancer.
A method for monitoring the response of a subject to a therapeutic treatment for an estrogen-induced cancer, the method comprising:
- (a) obtaining from a subject a first biological sample;
- (b) identifying the subject as having a level of expression of placental-like alkaline phosphatase 2 (ALPPL2) in the first biological sample that is greater than a threshold level;
- (c) selecting a therapy capable of treating an estrogen-induced cancer, wherein the therapy comprises a chemotherapy, a surgery, or radiotherapy;
- (d) administering the selected therapy to the subject;
- (e) obtaining from the subject a second biological sample after (d);
- (f) identifying the subject as having a level of expression of ALPPL2 in the second biological sample that is greater than a threshold level;
- and
- (g) administering to the subject an additional therapy capable of treating an estrogen-induced cancer, wherein the additional therapy comprises a chemotherapy, a surgery, or radiotherapy,
- wherein the estrogen-induced cancer is early-stage ovarian cancer or early-stage endometrial cancer.
A protocol for monitoring the efficacy of a therapeutic treatment for an estrogen-induced cancer, the protocol comprising:
- (a) obtaining from a subject a first biological sample;
- (b) identifying the subject as having a the-level of expression of placental-like alkaline phosphatase 2 (ALPPL2) in the first biological sample that is greater than a threshold level;
- (c) selecting a first therapy capable of treating an estrogen-induced cancer, wherein the first therapy is a chemotherapy, a surgery, or a radiotherapy;
- (d) administering the selected first therapy to the subject;
- (e) obtaining from the subject a second biological sample after (d);
- (f) determining a level of expression of ALPPL2 in the second biological sample;
- and
- (g) (i) if the level of expression of ALPPL2 in the second sample is at or greater than the threshold level, then administer a second therapy capable of treating estrogen-induced cancer to the subject, which is a different therapy than the first therapy, wherein the second therapy is a chemotherapy, a surgery, or a radiotherapy;
- and
- (ii) if the level of expression of ALPPL2 in the second sample is lower than the threshold level and the first therapy is a chemotherapy or a radiotherapy, then maintaining administration of the first therapy,
- wherein the estrogen-induced cancer is early-stage ovarian cancer or early-stage endometrial cancer.
Dependencies are inferred from the claim text.